Genetic stability of live attenuated vaccines against potentially pandemic influenza viruses

Kiseleva, Irina; Дубровина, И. А.; Федорова, Е А; Larionova, Natalie; Isakova–Sivak, Irina; Bazhenova, Ekaterina; Pisareva, Maria; Kuznetsova, Victoria; Flores, Jorge; Rudenko, Larisa

doi:10.1016/j.vaccine.2015.09.050

Cited by 5 publications

(7 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Phenotypic (cold adaptation and temperature sensitivity) and genotypic analyses conducted on the viruses recovered from the study subjects suggest that the vaccine is genetically stable after in vivo passage. These data confirmed our previous findings that not only seasonal, but also pandemic and potential pandemic LAIVs on an L17 MDV backbone are genetically and phenotypically stable after replication in humans [58][59][60][61].…”

Section: Discussionsupporting

confidence: 91%

A Phase 1 Randomized Placebo-Controlled Study to Assess the Safety, Immunogenicity and Genetic Stability of a New Potential Pandemic H7N9 Live Attenuated Influenza Vaccine in Healthy Adults

et al. 2020

Self Cite

View full text Add to dashboard Cite

This study describes a double-blind randomized placebo-controlled phase I clinical trial in healthy adults of a new potential pandemic H7N9 live attenuated influenza vaccine (LAIV) based on the human influenza virus of Yangtze River Delta hemagglutinin lineage (ClinicalTrials.gov Identifier: NCT03739229). Two doses of H7N9 LAIV or placebo were administered intranasally to 30 and 10 subjects, respectively. The vaccine was well-tolerated and not associated with increased rates of adverse events or with any serious adverse events. Vaccine virus was detected in nasal swabs during the 6 days after vaccination or revaccination. A lower frequency of shedding was observed after the second vaccination. Twenty-five clinical viral isolates obtained after the first and second doses of vaccine retained the temperature-sensitive and cold-adapted phenotypic characteristics of LAIV. There was no confirmed transmission of the vaccine strain from vaccinees to placebo recipients. After the two H7N9 LAIV doses, an immune response was observed in 96.6% of subjects in at least one of the assays conducted.

show abstract

Section: Discussionsupporting

confidence: 91%

A Phase 1 Randomized Placebo-Controlled Study to Assess the Safety, Immunogenicity and Genetic Stability of a New Potential Pandemic H7N9 Live Attenuated Influenza Vaccine in Healthy Adults

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…The MDVs for the Russian LAIV are A/ Leningrad/134/47/57 and B/USSR/60/69 [4,5]. The attenuation mutations in the US and Russian LAIVs have been identified [5][6][7][8], and both viruses are genetically and phenotypically stable following manufacture in embryonated eggs and following replication in vaccine recipients [9][10][11][12], likely because they bear several mutations in different gene segments, reducing the likelihood of reversion.…”

mentioning

confidence: 99%

How Live Attenuated Vaccines Can Inform the Development of Broadly Cross-Protective Influenza Vaccines

Rudraraju

Mordant

Subbarao

2019

The Journal of Infectious Diseases

View full text Add to dashboard Cite

“…Vaccine viruses isolated from the immunized ferrets were shown to preserve all attenuating mutations described for the Len–MDV [16]. Ferret challenge study demonstrated reasonable protection of ferrets vaccinated with Len–dP LAIV from severe respiratory damage and death after challenge with heterologous HPAIV A/turkey/Turkey/1/05 (H5N1) clade 2.2 [38]. …”

Section: Introductionmentioning

confidence: 99%

“…The intravenous pathogenicity index of tested viruses Len–dP [33], Len–VN, Len–tT and Len–VN/rg [17, 38] in chicken was 0. It means that no birds showed any clinical signs or died during the 10–day observation period after intravenous vaccine injection.…”

Section: Introductionmentioning

confidence: 99%

“…Clinical trials in 20 adult volunteers confirmed genetic stability of the Len–dP LAIV [15]. Genetic and phenotypic stability of another H5–LAIV candidate, Len–tT after replication in humans was also demonstrated [42, 43]. A number of coding mutations in internal genes responsible for attenuation of Len–17 MDV and Len–17 MDV–based reassortant LAIVs is well known [44-46].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Live Attenuated Reassortant Vaccines Based on A/Leningrad/134/17/57 Master Donor Virus Against H5 Avian Influenza

2017

Self Cite

View full text Add to dashboard Cite

Background:The H5N1 avian influenza was first recognized in humans in Hong Kong 20 years ago. Current enzootic spread of highly pathogenic H5N1 virus among wild and domestic poultry and a number of severe human respiratory diseases caused by this pathogen have stimulated necessity of development of potentially pandemic influenza vaccines.Discussion:In the past few years, significant research was conducted on how to prevent H5N1 influenza. Live, attenuated cold–adapted reassortant influenza vaccine (LAIV) is considered as one of the most promising candidates for pandemic and prepandemic vaccines. LAIV has proven to be safe and efficacious; pandemic LAIV might be more effective than inactivated vaccine in providing broader immune response.Conclusion:This review covers development of LAIVs against potential avian “pandemic” H5N1 subtype based on cold–adapted A/Leningrad/134/17/57 (H2N2) master donor virus backbone, and their preclinical and clinical studies.

show abstract

Genetic stability of live attenuated vaccines against potentially pandemic influenza viruses

Cited by 5 publications

References 35 publications

A Phase 1 Randomized Placebo-Controlled Study to Assess the Safety, Immunogenicity and Genetic Stability of a New Potential Pandemic H7N9 Live Attenuated Influenza Vaccine in Healthy Adults

A Phase 1 Randomized Placebo-Controlled Study to Assess the Safety, Immunogenicity and Genetic Stability of a New Potential Pandemic H7N9 Live Attenuated Influenza Vaccine in Healthy Adults

How Live Attenuated Vaccines Can Inform the Development of Broadly Cross-Protective Influenza Vaccines

Live Attenuated Reassortant Vaccines Based on A/Leningrad/134/17/57 Master Donor Virus Against H5 Avian Influenza

Contact Info

Product

Resources

About